Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia . Braz. J. Pharm. Sci. [Internet]. 2016 Dec. 1 [cited 2024 May 3];52(4):581-9. Available from: https://revistas.usp.br/bjps/article/view/128373